HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3

Gynecologic Oncology

Volumn 91, Issue 1, 2003, Pages 67-73

  Zielinski, G Denise ^a   Rozendaal, Lawrence ^a   Voorhorst, Feja J ^a   Berkhof, Johannus ^a   Snijders, Peter J F ^a   Risse, Elle J K ^a   Runsink, Arnold P ^b   De Schipper, Frits A ^c   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b District Laboratory Zeeland   (Netherlands)

^c Ziekenhuis Walcheren   (Netherlands)

Author keywords

HPV; Referral policy posttreatment of CIN 3; Treatment of CIN 3

Indexed keywords

ADENOCARCINOMA; ADULT; ARTICLE; BORDERLINE STATE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; CYTOLOGY; DISEASE COURSE; DYSKARYOSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; NETHERLANDS; PRIORITY JOURNAL; RECURRENT DISEASE; REDUCTION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA VULGARIS;

EID: 0141534451     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00415-3     Document Type: Article

References (36)

1. Natural history of cervical intraepithelial neoplasia a critical review . Int J Gynecol Pathol. 12:1993;186-192.
2. Nuovo J., Melnikow J., Willan A.R., Chan B.K.S. Treatment outcomes for squamous intraepithelial lesions. Int J Gynaecol Obstet. 68:2000;25-33.
3. Soutter W.P., de Barros Lopes A., Fletcher A., Monaghan J.M., Duncan I.D., Paraskevaidis E., et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet. 349:1997;978-980.
4. Heintz A.P.M. Patiënten met een afwijkende uitstijk; vervolg- en natraject. Ned Tijdschr Geneeskd. 131:1987;1953.
5. Follen Mitchell M., Tortolero-Luna G., Cook E., Whittaker L., Rhodes-Morris H., Silva E. A randomized clinical trial of cryotherapy, laser vaporization and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol. 92:1998;737-744.
6. Bigrigg A., Haffenden D.K., Sheehan A.L., Codling B.W., Read M.D. Efficacy and safety of large-loop excision of the transformation zone. Lancet. 343:1994;32-34.
7. Zaitoun A.M., McKee G., Coppen M.J., Thomas S.M., Wilson P.O.G. Completeness of excision and follow up cytology in patients treated with loop excision biopsy. J Clin Pathol. 53:2000;191-196.
8. Narducci F., Occelli B., Boman F., Vinatier D., Leroy J.-L. Positive margins after conization and risk of persistent lesion. Gynecol Oncol. 76:2000;311-314. (doi:10.1006/gyno.1999.5697).
9. Baldauf J.-J., Dreyfus M., Ritter J., Cuenin C., Tissier I., Meyer P. Cytology and colposcopy after loop electrosurgical excision implications for follow-up . Obstet Gynecol. 92:1998;124-130.
10. Hulman G., Pickles C.J., Gie C.A., Dowling F.M., Stocks P.J., Dixon R. Frequency of cervical intraepithelial neoplasia following large loop excision of the transformation zone. J Clin Pathol. 51:1998;375-377.
11. Lu C.-H., Liu F.-S., Tseng J.-J., Shih-Chu Ho E. Predictive factors for residual disease in subsequent hysterectomy following conization for CIN III. Gynecol Oncol. 79:2000;284-288. (doi:10.1006/gyno.2000.5949).
12. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 64. Human papillomaviruses. Lyon, France: International Agency for Research on Cancer, 1995.
13. Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:1999;12-19.
14. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer a worldwide perspective . J Natl Cancer Inst. 87:1995;796-802.
15. Chua K.-L., Hjerpe A. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol. 66:1997;108-113.
16. Bollen L.J.M., Tjong-A-Hung S.P., van der Velden J., Mol B.-W., ten Kate F.W.J., ter Schegget J., et al. Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology. Gynecol Oncol. 72:1999;199-201. (doi:10.1006/gyno.1998.5250).
17. Nagai Y., Maehama T., Asato T., Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3 is it an alarm for disease recurrence? Gynecol Oncol. 79:2000;294-299. (doi:10.1006/gyno.2000.5952).
18. Nobbenhuis M.A.E., Meijer C.J.L.M., van den Brule A.J.C., Rozendaal L., Voorhorst F.J., Risse E.K.J., et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer. 84:2001;769-801. (doi:10.1054/bjoc.2000.1689).
19. Vooijs G.P. De advisering bij afwijkende bevindingen van cytologisch onderzoek van de cervix uteri. Ned Tijdschr Geneeskd. 131:1987;1662-1663.
20. Solomon D., Davey D., Kurman R., Moriarty A., O'Connor D., Prey M., et al. The 2001 Bethesda System terminology for reporting results of cervical cytology . JAMA. 287:2002;2114-2119.
21. Hanselaar A.G. Criteria for organized cervical screening programs. Special emphasis on The Netherlands program. Acta Cytol. 46:2002;619-629.
22. Lörincz A. Hybrid Capture method for detection of human papillomavirus DNA in clinical specimens. Papillomavirus Rep. 7:1996;1-5.
23. Rozendaal L., Walboomers J.M.M., van der Linden J.C., Voorhorst F.J., Kenemans P., Helmerhorst ThJM, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer. 68:1996;766-769.
24. Lin C.-T., Tseng C.-J., Lai C.-H., Hsueh S., Huang K.-G., Huang H.-J., et al. Value of human papillomavirus deoxyribonucleic acid testing after conization in the prediction of residual disease in the subsequent hysterectomy specimen. Am J Obstet Gynecol. 184:2001;940-945.
25. Jain S., Tseng C.-J., Horng S.-G., Soong Y.-K., Pao C.C. Negative predictive value of human papillomavirus test following conization of the cervix uteri. Gynecol Oncol. 82:2001;177-180. (doi:10.1006/gyno.2001.6241).
26. Cruickshank M.E., Sharp L., Chambers G., Smart L., Murray G.Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia. Int J Gynaecol Obstet. 109:2002;579-581.
27. Elfgren K., Bistoletti P., Dillner L., Walboomers J.M.M., Meijer C.J.L.M., Dillner J. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol. 174:1996;937-942.
28. Distéfano, AL, Picconi MA, Alonio LV, Dalbert D, Mural J, Bartt O. Persistence of human papillomavirus DNA in cervical lesions after treatment with diathermic large loop excision.Infect Dis Obstet Gynecol1998; 214-9.
29. Paraskevaidis E., Koliopoulos G., Alamanos Y., Malamou-Mitsi V., Lolis E.D., Kitchener H.C. Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynecol. 98:2001;833-836.
30. Kucera E., Sliutz G., Czerwenka K., Breitenecker G., Leodolter S., Reinthaller A. Is high-risk human papillomavirus infection associated with cervical intraepithelial neoplasia eliminated after conization by large-loop excision of the transformation zone? Eur J Obstet Gynecol Reprod Biol. 100:2001;72-76.
31. Nobbenhuis M.A.E., Helmerhorst T.J.M., van den Brule A.J.C., Rozendaal L., Voorhorst F.J., Bezemer P.D., et al. Cytological regression and high-risk HPV clearance in women referred for colposcopy because of an abnormal cervical smear. Lancet. 358:2001;1782-1783.
32. Zielinski G.D., Snijders P.J.F., Rozendaal L., Voorhorst F.J., Runsink A.P., de Schipper F.A., et al. High-risk HPV testing in women with borderline and mild dyskaryosis long-term follow-up data and clinical relevance . J Pathol. 195:2001;300-306. (doi:10.1002/path.981).
33. Meijer C.J.L.M., Rozendaal L., Van der Linden J.C., Helmerhorst ThJM, Voorhorst F.J., Walboomers J.M.M. Human papillomavirus testing for primary cervical cancer screening. Franco E., Monsonego J. New developments in cervical cancer screening and prevention. 1997;338-347 Blackwell Science, Oxford.
34. Raab S.S. Can glandular lesions be diagnosed in Pap smear cytology? Diagn Cytopathol. 23:2000;127-133.
35. Zielinski G.D., Snijders P.J.F., Rozendaal L., Voorhorst F.J., van der Linden H.C., Runsink A.P., et al. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. BJC. 85:2001;398-404. (doi:10.1054/bjoc.2001.1926).
36. Walboomers J.M.M., de Roda Husman A.-M., Snijders P.J.F., Stel H.V., Risse E.K.J., Helmerhorst T.J.M., et al. Human papillomavirus in false negative archival cervical smears implications for screening for cervical cancer . J Clin Pathol. 48:1995;728-732.